
Cell

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy

Graphical Abstract



Authors

Joan Montero, Kristopher A. Sarosiek, ..., Ronny Drapkin, Anthony Letai

Correspondence

anthony_letai@dfci.harvard.edu

In Brief

Dynamic BH3 Profiling takes a functional approach to precision medicine in cancer by measuring early changes in death signaling in tumor cells induced by drugs. These changes predict tumor cell killing in vitro, in vivo, and in the clinic.

Highlights

- Early death signaling predicts cytotoxicity days before cell death occurs
- Dynamic BH3 Profiling (DBP) is a functional measure of death signaling
- DBP predicts response to targeted agents in vitro and in vivo
- DBP is a potential tool for personalizing cancer therapy



